What’s in issue 16?
• We reveal the key findings from our patient involvement survey, which highlights regional and gender differences in levels of engagement and finds more than a quarter of people will wait for side effects to be limiting or unbearable before discussing them with a doctor.
• BASELINE Editor Robert Fieldhouse interviews one of the world’s leading HIV doctors Cal Cohen from Harvard in the USA to learn about Gilead’s 4-in-1 blockbuster drug Stribild that’s just received European Approval.
• Roy Kilpatrick, former Chief Executive of HIV Scotland discusses Integrated Care Pathways, which promise to help us guide our way through an ever changing NHS.
• KathyHIVBird shares the learnings and outcomes from the Between the Sheets Meeting in Liverpool, which brought one third of all women living with HIV in the region together to define the issues important to them.
• In our hepatitis section two readers share their experience of taking hepatitis C treatment.